AUSTRALIA ANTIGEN (HBsAG) IN INSTITUTIONALISED SCHIZOPHRENICS by Chaudhury, S. et al.
...mJ. I'syduat., 1W3, 35(1), 31-32 
AUSTRALIA ANTIGEN (HBsAG) IN INSTITUTIONALISED 
SCHIZOPHRENICS 
S.CHAUDHURY, S.CHANDRA, G.S.CHOPRA, M.AUGUSTINE 
SUMMARY 
In a study of sixty institutionalist Schizophrenic patients, sixty chronic schizophrenic outpatients and an equal 
number of age and sex matched normal controls from the same regional background, the prevalence of HBsAG was 
six, one and zero respectively. Institutionalized schizophrenic patients are a high risk group for hepatitis B virus 
infection. 
INTRODUCTION 
Transmission of hepatitis Bvirus(HBV) through blood 
transfusion, plasma concentrates, contaminated needles, 
syringes or through small breaks in the skin as well as 
homo and heterosexual activities is well established. In 
addition, suggested means of person to person transfer 
include kissing (Villarejos, 1974), biting (McGuarries, 
1
(>74), sharing of razors and toothbrushes (Mosley, 1975) 
tattooing and scarification. The role of spread by insect 
vectors is still unclear (Wright, 199(1). Studies have shown 
a high incidence of HBsAG in parenteral drug users, male 
homosexuals, immunosuppressed patients, hemophiliacs, 
patients on dialysis, health care workers, ambulance per-
sonnel and in institutions like retirement homes, institu-
tions for the mentally retarded and prisons, and also to a 
lesser extent among family members of chronically in-
f fected persons (Wright, 1990; Dienstag, 1991). 
Some chronic schizophrenic patients are institutional-
ized for prolonged periods. They are prone to violent 
behavior and are often given parenteral injections; they 
also undergo various laboratory tests for which blood is 
drawn. Little is known about their sexual habits. No study 
has yet been carried out to determine the prevalence of 
HBsAG in these patients. The paucity of work in this field 
promoted us to undertake a study to determine the 
prevalence of HBsAG in institutionalized schizophrenic 
patients. 
MATERIAL AND METHODS 
The patient sample consisted of all male patients ad-
mitted to Mental Hospital, Bareilly for more than five 
years and meeting the DSM-III R criteria for 
schizophrenia. Equal number of age and sex matched 
normal subjects without any physical or mental illness 
formed the normal control group. Another control group 
consisted of equal number of outpatients meeting DSM-III 
R criteria for schizophrenia and symptomatic for at least 
five years but who had never been admitted to any mental 
hospital. Both the control groups were from the same 
regional background as the institutionalized group. 
Exclusion criteria for patients and controls were as 
follows: 
1. Past history of jaundice. 
2. Clinical evidence of jaundice or hepatomegaly. 
All patientsand controls were examined independently 
by two psychiatrists to confirm the diagnosis and the 
absence of exclusion criteria; they were included in the 
study only after the concurrence of both psychiatrists. 
Blood samples were collected by venepuncture and 
immediately transferred to the pathology laboratory of 
Mental Hospital, Bareilly where the serum was separated 
and stored. The pathologist was blind as to whether the 
sample was from patient or control group. Detection of 
HBsAG was done by the Reversed Passive I lemagglutina-
tion Test (Horowitz et al, 1977a, 1977b) using Rapadex B 
Kits supplied by Orthodiagnostic systems, Bombay. In 
addition liver function test, SGOT& SGPT(Varley, 1987) 
were also performed. Statistical comparisons were carried 
out by the Chi-square test (with Yates correction). 
RESULTS 
The mean and range of age of the patients and controls 
are given in Table 1. here The mean duration of 
hospitalization of institutionalized schizophrenic patients 
Table 1: 
Comparison of institutionalized schizophrenics, non-institu-
tionalized chronic schizophrenics and normal controls. 
Institutionalized Non-institutionalized Normal 
Schizophrenics Schizophrenics controls 
(n = 60) (n = 60) (n = 60) 
Mean age 50.43 42.6 50.43 
in years (30-89) (26-69) (30-89) 
Mean duration 18.7 
(range) of hospit- (5 to 49) 
alizarjon in years 
HBs Ag Positive 6 1 
was 18.7 years (range 5 years to 49 years). The liver 
function tests, SGOT & SGPT of all the patients and 
controls were within normal limits. Six out of the sixty 
hospitalized schizophrenic patients were positive for 
HBsAG compared to one of the non institutionalized 
schizophrenic patients and none of the sixty normal sub-
jects. The difference was statistically significant (X = 
9.22;df=2;p<0.01). 
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DISCUSSION  REFERENCES 
The major finding of our study was that institutional-
ized schizophrenics had a significantly higher incidence 
of HBsAG us compared to normal controls and also non-
institutionalized chronic schizophrenics. 'litis being the 
first study of its type, comparisons with other studies was 
not possible. However, in our opinion, this high incidence 
is a very important finding and similar studies must be 
carried out in other mental hospitals. 
The reasons for such a high carrier rate remains un-
clear. Nosocomial transmission is probably the most likely 
cause in our setting where needles and syringes are boiled 
before use and not autoclaved. Spread through shared 
razors and homosexual practices also cannot be ruled out 
since the patients remain in closed wards for prolonged 
periods. However, on interview none of carriers admitted 
to indulging in homosexual practices. 
Accordi ng to conservative World Health Organization 
estimates (Soheslavsky, 1980) it is believed that over one 
billion people in the world have been infected by HBV, 
over 200 billion are chronic carriers and over two million 
die annually of thedisease. In India there are about twenty 
million carriers, about 25% of whom may develop cir-
rhosis and/or liver cancer (Joshi, 1988). The disease is 
incurable and till recently the only known preventive 
measure was avoiding contact with infective blood and 
other body fluids Ihe recent introduction of a safe and 
effective vaccine has changed this gloomy outlook. How-
ever, due to high cost universal immunization is not prac-
ticable. !"he currently preferred strategy is todefine groups 
which are at high risk and to offer them immunization 
against HBV (Wright, 1990). Our study is a step in iden-
tifying a hitherto unrecognized group of patients who are 
at high risk for HBV infection. 
We conclude from our study that chronic institutional-
ized psychotic patients are a high risk group for HBV 
infection and are likely to benefit from immunization 
against HBV. 
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